Next-generation therapies for degenerative eye diseases
Gene Therapy: Protecting Sight at the Source
Our gene therapy technology offers a promising approach to treating degenerative eye diseases—such as glaucoma and optic neuropathies—by targeting the underlying causes of vision loss rather than just managing symptoms. By delivering protective genes or silencing harmful ones, this therapy can help safeguard retinal ganglion cells and preserve eyesight. Unlike conventional treatments, gene therapy has the potential to provide long-lasting benefits.
Precision Nanodelivery for Degenerative Eye Diseases
Effective gene therapy begins with precise delivery. Our advanced nanodelivery system targets retinal ganglion cells (RGCs)—the neurons responsible for carrying visual signals from the eye to the brain.
By transporting therapeutic agents or CRISPR-Cas tools directly to these cells, our platform ensures treatment reaches the true site of disease progression.
This targeted precision enhances therapeutic effectiveness while minimising off-target effects, paving the way for safer, more impactful treatments for degenerative eye diseases such as glaucoma and optic neuropathies—protecting vision where it matters most.
Smart Delivery: From Eye Drop to Retina
Our smart nanoparticle system can carry therapeutic agents from a simple eye drop all the way to the retinal ganglion cells in retina, crossing natural barriers that have long limited treatment options.
This non-invasive innovation enables both drugs and CRISPR gene-editing tools to reach the specific cells responsible for vision.
By making deep-tissue delivery possible without surgery, it opens the door to transformative therapies for degenerative eye diseases.